Biopharma SHAKTI Scheme

I have sufficient grounded facts. Writing the note now.

Biopharma SHAKTI Scheme — UPSC Study Note

Biopharma SHAKTI = Strategy for Healthcare Advancement through Knowledge, Technology & Innovation — a Union scheme to build a globally competitive domestic ecosystem for biologics and biosimilars [S1][S3].
Outlay of ₹10,000 crore over five years, announced in Union Budget 2026-27 under the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [S1][S2].
Aspirants must know it as India's flagship push to move beyond generic/conventional pharma into advanced biologics, biosimilars, gene therapy, and bio-manufacturing, complementing PLI-Pharma and BioE3 policy [S2][S3].

PIB clarification (17 March 2026) by Department of Pharmaceuticals reiterating the scheme's outlay and seven components; "contours of the scheme are under deliberation" [S1].
Originally proposed in Union Budget 2026-27 speech as part of the push to scale manufacturing in 7 strategic frontier sectors [S3][S4].
Union Minister Dr. Jitendra Singh flagged it as catalysing India's role in the "next industrial revolution" and a global bio-manufacturing hub [S2].

Builds upon earlier biotech-pharma interventions: National Biopharma Mission (NBM, 2017) by DBT-BIRAC (World Bank co-funded, USD 250 mn) and PLI Scheme for Pharmaceuticals (2021) [S3].
Aligned with the BioE3 Policy (2024) of the Department of Biotechnology — Biotechnology for Economy, Environment & Employment [S3].
Announced in Union Budget 2026-27 by Finance Minister; PIB explainer issued Feb 2026; detailed component-wise PIB release on 17 Mar 2026 [S1][S3].

Nodal Ministry: Ministry of Chemicals & Fertilizers — Department of Pharmaceuticals (DoP) [S1].
Outlay: ₹10,000 crore over 5 years [S1][S2].
Target market share: capture ~5% of the global biopharmaceutical market [S3].
Seven Components [S1][S3]: 1. Biopharma Discovery Grant Fund & Discovery & Development Equity Fund. 2. Biopharma-focused NIPER Network + National Biopharma R&D Network (3 new NIPERs + upgradation of 7 existing NIPERs) [S2]. 3. India Clinical Trial Sites Network — 1,000 accredited sites [S1][S3]. 4. Fermentation-based Bulk Drugs & Building Blocks Manufacturing Incentive. 5. Biopharma Delivery Devices & Packaging Manufacturing Ecosystem. 6. Biosimilars & Emerging Biologics Manufacturing Initiative. 7. Regulatory Strengthening — dedicated Scientific Review Cadre in CDSCO, including specialists for gene therapy [S2][S3].

Economic: Reduces import dependence on biologics (high-value imports), targets 5% of global biopharma market, expands bioeconomy beyond conventional generics [S2][S3].
Scientific / Technological: Pivot to gene therapy, biosimilars, fermentation-based APIs; institutional R&D backbone via NIPER expansion and biopharma R&D network [S2].
Administrative / Regulatory: Modernises CDSCO with specialist reviewer cadre to deliver "global-best drug review standards and approval timeframes" [S2][S3].
Strategic: Frames biopharma as a frontier strategic sector under Budget 2026-27's 7-sector manufacturing scale-up; positions India as a global biomanufacturing hub [S2][S4].
Social: Aims to support affordable healthcare by domesticising biologics/biosimilars production [S1].

Feb 2026: Biopharma SHAKTI announced in Union Budget 2026-27 [S3][S4].
Feb 2026: PIB Budget Series explainer "Transforming India into a Global Biopharma Hub" published [S3].
17 Mar 2026: DoP PIB release confirms ₹10,000 cr outlay, lists 7 components, notes contours under deliberation [S1].
Coupled budgetary push: provision flagged for BioPharma SHAKTI alongside 3 dedicated Chemical Parks [S4].

SHAKTI expands to Strategy for Healthcare Advancement through Knowledge, Technology & Innovation [S3].
Outlay = ₹10,000 crore / 5 years [S1].
Nodal department = Department of Pharmaceuticals (NOT DBT, NOT MoHFW) [S1].
Parent ministry = Ministry of Chemicals & Fertilizers [S1].
Announced in Union Budget 2026-27 [S3].
1,000 accredited clinical trial sites proposed under India Clinical Trial Sites Network [S1][S3].
3 new NIPERs + 7 upgraded NIPERs under the NIPER Network component [S2].
Regulatory body to be strengthened = CDSCO (Central Drugs Standard Control Organisation) [S2].
Includes Fermentation-based Bulk Drugs & Building Blocks incentive [S1].
Focus areas = biologics, biosimilars, gene therapy, delivery devices & packaging [S2][S3].
Predecessor mission = National Biopharma Mission (2017) under DBT-BIRAC [S3].
Target = capture ~5% of global biopharma market [S3].

GS-III — Indian Economy (manufacturing, growth); Science & Technology (indigenisation, biotech, IPR); Health.
Syllabus headings: "Achievements of Indians in S&T; indigenisation of technology"; "Government Budgeting"; "Issues relating to development & management of social sector — Health".
Possible question stems:
"The Biopharma SHAKTI scheme marks a shift from a generics-led pharma economy to a biologics-led bioeconomy. Examine."
"Discuss the role of regulatory reform (CDSCO) and clinical trial infrastructure in making India a global biopharma hub."
"Critically assess fiscal incentives like Biopharma SHAKTI in reducing India's import dependence in high-value biologics."

BioE3 Policy 2024 — overarching biotech policy framework.
National Biopharma Mission (NBM) & BIRAC — predecessor and implementing biotech body.
PLI Scheme for Pharmaceuticals & Bulk Drugs — sister manufacturing-incentive scheme.
CDSCO & New Drugs and Clinical Trials Rules 2019 — regulatory backbone.
NIPERs — institutional pharma R&D ecosystem.
India's Generic Pharma Industry / "Pharmacy of the World" — comparative base.
Bulk Drug Parks Scheme — addresses upstream API dependency.
Genome India Programme, gene therapy approvals — frontier biotech context.

Confusing nodal body: it is Department of Pharmaceuticals (Min. of Chemicals & Fertilizers), NOT Department of Biotechnology (DBT) or MoHFW.
Confusing with National Biopharma Mission (2017, DBT-BIRAC, World Bank-aided) — that is a predecessor, not Biopharma SHAKTI.
SHAKTI ≠ the SHAKTI coal-linkage policy of Ministry of Coal — same acronym, unrelated.
Outlay is ₹10,000 cr / 5 yrs; a related PIB op-ed mentions ₹13,000 cr combining Biopharma SHAKTI + 3 Chemical Parks — do not conflate [S1][S4].
Clinical trial sites figure is 1,000 accredited sites, not 100 or 10,000.

[S1] Biopharma SHAKTI Scheme — Department of Pharmaceuticals — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2241168 — (tier: 1)
[S2] Budget 2026-27 announcement of "Biopharma Shakti" … Dr. Jitendra Singh — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221778 — (tier: 1)
[S3] Transforming India into a Global Biopharma Hub — Budget 2026-27 Series — https://static.pib.gov.in/WriteReadData/specificdocs/documents/2026/feb/doc202622776701.pdf — (tier: 1)
[S4] Provision of Rs 13,000 cr for BioPharma SHAKTI & 3 Dedicated Chemical Parks — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2235160 — (tier: 1)